Spyre Therapeutics, Inc. $SYRE Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 9.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,656,164 shares of the company’s stock after selling 172,845 shares during the period. Janus Henderson Group PLC’s holdings in Spyre Therapeutics were worth $83,587,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Capital International Investors increased its stake in shares of Spyre Therapeutics by 46.0% during the 4th quarter. Capital International Investors now owns 3,492,541 shares of the company’s stock worth $114,416,000 after purchasing an additional 1,100,000 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Spyre Therapeutics by 483.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 275,984 shares of the company’s stock valued at $4,625,000 after buying an additional 228,705 shares in the last quarter. Vanguard Group Inc. lifted its stake in Spyre Therapeutics by 32.3% in the 4th quarter. Vanguard Group Inc. now owns 4,035,074 shares of the company’s stock valued at $132,189,000 after buying an additional 984,344 shares in the last quarter. Seven Grand Managers LLC acquired a new stake in Spyre Therapeutics during the 4th quarter valued at $3,276,000. Finally, UBS Group AG increased its position in Spyre Therapeutics by 76.5% during the fourth quarter. UBS Group AG now owns 680,566 shares of the company’s stock worth $22,295,000 after buying an additional 294,977 shares in the last quarter. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Analysts Set New Price Targets

SYRE has been the subject of a number of recent research reports. BTIG Research lifted their price objective on Spyre Therapeutics from $98.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, June 15th. Mizuho upped their target price on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wolfe Research cut shares of Spyre Therapeutics from an “outperform” rating to a “peer perform” rating in a research note on Tuesday. Leerink Partners lifted their price target on shares of Spyre Therapeutics from $49.00 to $106.00 and gave the stock an “outperform” rating in a report on Monday, April 13th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Spyre Therapeutics from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $101.42.

Insiders Place Their Bets

In other news, insider Sheldon Sloan sold 8,334 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $87.70, for a total transaction of $730,891.80. Following the completion of the transaction, the insider owned 8,334 shares of the company’s stock, valued at $730,891.80. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 7,500 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $87.74, for a total transaction of $658,050.00. Following the transaction, the chief financial officer owned 97,994 shares in the company, valued at approximately $8,597,993.56. The trade was a 7.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 176,667 shares of company stock worth $14,177,617 over the last 90 days. Corporate insiders own 15.69% of the company’s stock.

Spyre Therapeutics Stock Down 3.1%

Shares of NASDAQ:SYRE opened at $98.33 on Friday. The company has a market cap of $8.65 billion, a P/E ratio of -47.27 and a beta of 3.02. The business has a fifty day simple moving average of $88.23 and a 200-day simple moving average of $62.99. Spyre Therapeutics, Inc. has a 52 week low of $14.51 and a 52 week high of $105.09.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.08). Sell-side analysts expect that Spyre Therapeutics, Inc. will post -2.86 earnings per share for the current fiscal year.

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.